Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels.

Hyeong Seok Kim Mirang Lee Youngmin Han Jae-Seung Kang Yoon Hyung Kang Hee Ju Sohn Wooil KwonDong Ho LeeJin-Young Jang

Published in: Journal of hepato-biliary-pancreatic sciences (2023)

Neoadjuvant treatment showed better survival than upfront surgery in resectable pancreatic cancer. In patients with PV/SMV contact or CA19-9 >150 U/mL, NAT showed a survival difference compared to upfront surgery; therefore, NAT could be considered in these patients.

Keyphrases

locally advanced
minimally invasive
rectal cancer
lymph node
end stage renal disease
coronary artery bypass
ejection fraction
chronic kidney disease
prognostic factors
atrial fibrillation